이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!
Terns Pharmaceuticals 관리
관리 기준 확인 1/4
현재 CEO에 대한 정보가 충분하지 않습니다.
주요 정보
Amy Burroughs
최고 경영자
n/a
총 보상
| CEO 급여 비율 | n/a |
| CEO 임기 | less than a year |
| CEO 소유권 | n/a |
| 경영진 평균 재임 기간 | less than a year |
| 이사회 평균 재임 기간 | 3.8yrs |
최근 관리 업데이트
Recent updates
Terns Pharmaceuticals: Obesity Advancement Continues With Other Q1 2025 Program Catalyst
Sep 25Terns Pharmaceuticals: Weight Loss Drug TERN-601 Is Competitive
Sep 10We Think Terns Pharmaceuticals (NASDAQ:TERN) Can Afford To Drive Business Growth
Aug 18
Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
May 03Terns Pharmaceuticals (NASDAQ:TERN) Is In A Good Position To Deliver On Growth Plans
Jan 12We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Sep 29Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Jun 06Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Feb 21Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Oct 03Terns Pharmaceuticals: The Easy Money Has Been Made
Sep 20Terns Pharmaceuticals GAAP EPS of -$0.55 beats by $0.08
Aug 08Is Terns Pharmaceuticals (NASDAQ:TERN) In A Good Position To Deliver On Growth Plans?
Jun 14Companies Like Terns Pharmaceuticals (NASDAQ:TERN) Are In A Position To Invest In Growth
Mar 16We're Not Very Worried About Terns Pharmaceuticals' (NASDAQ:TERN) Cash Burn Rate
Nov 24We're Hopeful That Terns Pharmaceuticals (NASDAQ:TERN) Will Use Its Cash Wisely
Aug 24Terns Pharma gains 9% on positive TERN-101 data in mid-stage NASH study
Jun 14CEO
Amy Burroughs (54 yo)
less than a year
테뉴어
Ms. Amy L. Burroughs, M.B.A., serves as CEO & Director at Terns Pharmaceuticals, Inc. from February 07, 2024. She serves as Independent Director of Tenaya Therapeutics, Inc. since December 2022. She had be...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CFO & Treasurer | 4.2yrs | US$3.14m | 0.027% $ 190.1k | |
| CEO & Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Legal Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Research | 2.8yrs | 데이터 없음 | 데이터 없음 | |
| Chief Medical Officer | 1.4yrs | 데이터 없음 | 데이터 없음 | |
| Chief Business Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Chief Development Officer | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Medical Affairs | less than a year | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs & Quality Assurance | less than a year | 데이터 없음 | 데이터 없음 | |
| VP of Finance & Controller | less than a year | 데이터 없음 | 데이터 없음 |
0.8yrs
평균 재임 기간
46.5yo
평균 연령
경험이 풍부한 관리: TERN 의 관리팀은 경험 (평균 재직 기간 1.1 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| CEO & Director | less than a year | 데이터 없음 | 데이터 없음 | |
| Independent Director | 6yrs | US$298.99k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$304.99k | 0% $ 0 | |
| Independent Director | 4.5yrs | US$299.99k | 0.56% $ 3.9m | |
| Member of Scientific Advisor | no data | 데이터 없음 | 데이터 없음 | |
| Independent Chairman | 3.8yrs | US$340.15k | 0% $ 0 | |
| Member of Scientific Advisor | no data | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisor | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 2.3yrs | US$303.06k | 0% $ 0 | |
| Member of Scientific Advisor | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 3.8yrs | US$480.49k | 0.018% $ 123.0k | |
| Independent Director | 3.1yrs | US$302.49k | 0% $ 0 |
3.8yrs
평균 재임 기간
56.5yo
평균 연령
경험이 풍부한 이사회: TERN 의 이사회는 경험(평균 재직 기간 3.5 년)으로 간주됩니다.